Canadian Company to Export Medical Marijuana Products to EU
Tilray, a Canadian company specializing in medical marijuana production and research, became the first medical cannabis company that received all necessary permits to sell their products to European medical marijuana patients. Thanks to the efforts of the Croatian Committee of Medical Cannabis, the local legislation has been changed, and Croatians qualifying for medical marijuana have finally got an opportunity to buy Tilray Liquid Capsules.
Tilray considers itself a global leader in the medical marijuana market; the company is devoting its activity to the science and safety of medical cannabis for patients suffering from many debilitating illnesses including cancer, multiple sclerosis, and epilepsy. Moreover, the company participates in conducting various medical marijuana studies in cooperation with researchers in North America, Australia, and the European Union.
Tilray is licensed to legally import their orally administered medical marijuana products containing the active weed compounds like cannabidiol (CBD) and tetrahydrocannabinol (THC) for commercial use into the EU. The company has already shipped the first batch of their medical cannabis products to Croatian pharmacies to be sold to local patients with prescriptions for medical marijuana.
In the near future, Croatian patients will able to benefit from two formulations of Tilray products. One of them will contain 5.0 mg of CBD or THC per capsule while another one will include 2.5 mg of THC and 2.0 mg of CBD per capsule. Thanks to the content of both primary cannabis compounds, patients will be able to take a precise dosage of medicine with the minimum risk of experiencing any side effects. All the products of the company are manufactured at licensed facilities in Canada. In addition, the quality of medicine supplied to Croatia will also be overseen by the Croatian Institute of Immunology.
The Tilray products will soon be available in Croatian pharmacies for patients with chronic pain, Dravet syndrome, epilepsy, multiple sclerosis, nausea, and HIV/AIDS. Unlike some other drugs prescribed to people with the aforementioned medical conditions, the products supplied by Tilray often have fewer downsides and better safety profile.
Though the process of complying with all requirements of the Canadian and Croatian regulatory authorities took a good deal of time, Brendan Kennedy, Tilray President, is pleased that his company became the first legal supplier of medical marijuana products to the European Union. Kennedy sees a great potential in the medical marijuana sector in Europe and hopes his company will have an opportunity to import their products to other European countries in the near future.
While the number of medical cannabis patients in Canada is lower than many in the marijuana industry had initially expected, there is a constant increase of medical cannabis demand in Croatia. In addition, Tilray has already announced the expansion of their global presence by importing their medical marijuana products to Australia for treating medical cannabis patients.
